

## Appendix A: MRFF Stem Cell Therapies Mission projects funded as of March 2023

As of March 2023, the Medical Research Future Fund's [Stem Cell Therapies Mission](#) has had 5 grant opportunities that have awarded funding for 47 research projects. The grant opportunities are:

1. [2020 Stem Cell Therapies Research Grant Opportunity](#) (1)
2. MRFF Coronavirus Research Response 2020 Rapid Screening of Approved Drugs in Stem Cell Models for COVID-19 Treatment Grant Opportunity\*
3. [2020 Stem Cell Therapies Mission Research Grant Opportunity](#) (2)
4. [2021 Stem Cell Therapies Mission Research Grant Opportunity](#)
5. [2022 Stem Cell Therapies Mission Research Grant Opportunity](#)

The below table outlines the projects funded from these grant opportunities, and the 'Priority area/s for investment' as outlined in the [Implementation Plan](#) that each project targets. Further information on MRFF funded grants is available [here](#).

Institution	Project Title	Amount (ex GST)	Funded from Grant Opportunity
<b>Implementation Plan Priority Area 1.1</b>			
Monash University	Developing novel cellular therapies and tissue engineering approaches for the treatment of muscle injury and wasting disorders using tissue resident muscle stem cells	\$ 824,480.00	1 (Stream 1)
Monash University	Engineering a solution to non-alcoholic steatohepatitis through tuning substrate stiffness	\$ 472,680.00	1 (Stream 1)

\*Guidelines may be requested by emailing [MRFF@health.gov.au](mailto:MRFF@health.gov.au).

Institution	Project Title	Amount (ex GST)	Funded from Grant Opportunity
Monash University	Human Amniotic Epithelial Stem Cells as Novel Treatment for Autoimmune Vasculitis	\$ 588,396.00	1 (Stream 1)
University of Melbourne	Next generation stem cell therapy for Parkinson's disease.	\$ 952,873.50	1 (Stream 1)
Curtin University	Optimizing a preclinical model for bioprinting skin aimed at repairing skin loss in patients	\$ 737,689.50	1 (Stream 1)
Murdoch Children's Research Institute	Evaluating safety and efficacy of bioengineered heart tissue for congenital heart repair	\$ 998,838.15	3 (Stream 1)
University of Melbourne	Stem cell therapies for digestive disease	\$ 583,614.00	3 (Stream 1)
The Walter and Eliza Hall Institute of Medical Research	A novel stem cell-derived manufacturing platform for next-generation dendritic cell vaccines	\$ 909,695.60	5 (Stream 1)
St Vincent's Institute of Medical Research	Bio-engineering vascularized skin flaps for complex wound reconstruction	\$ 710,793.20	5 (Stream 1)
Centre for Eye Research Australia Limited	Development of a photoreceptor regenerative therapy to treat blindness	\$ 587,569.30	5 (Stream 1)
Monash University	Intracerebral delivery of Neuropeptide Y through hiPSC-derived progenitors (NPY-hiPSC- NPs) as a disease-modifying treatment for drug-resistant epilepsy	\$ 671,512.00	5 (Stream 1)
St Vincent's Institute of Medical Research	PAGETURNA: Pioneering Application of Gene Editing in Transplant Using RNA	\$ 979,980.00	5 (Stream 1)

Institution	Project Title	Amount (ex GST)	Funded from Grant Opportunity
University of Sydney	Purification and cryopreservation of an allogeneic stem cell-derived photoreceptor cell product	\$ 515,340.00	5 (Stream 1)
University of Sydney	Transforming corneal stem cell-based therapies with innovative bioengineered technologies	\$ 567,683.00	5 (Stream 1)
<b>Implementation Plan Priority Area 1.2</b>			
University of Melbourne	Cartilage based stem cell therapies for joint deformity and facial disfigurement. A framework for point-of-care manufacturing and delivery (ARISTOCRAT)	\$ 6,999,671.10	4 (Stream 1)
University of Sydney	Development of photoreceptor cell therapy to treat blindness.	\$ 2,566,652.72	4 (Stream 1)
Cartherics Pty Ltd	Gene modified pluripotent stem cells to generate and empower innate immune cells against poor-prognosis cancers	\$ 5,376,696.00	4 (Stream 1)
University of Melbourne	Necessary steps to advance a pluripotent stem cell-derived tissue repair therapy to the clinic for stroke	\$ 2,065,971.00	4 (Stream 1)
<b>Implementation Plan Priority Area 1.3</b>			
University of Sydney	Induced pluripotent stem cell derived cardiomyocytes: a new therapy for “no-option” end stage heart failure	\$ 4,978,360.66	3 (Stream 2)
Monash University	Locally administered extracellular vesicles for perianal fistulising Crohn's disease	\$ 935,629.60	3 (Stream 2)

Institution	Project Title	Amount (ex GST)	Funded from Grant Opportunity
<b>Implementation Plan Priority Area 2.1</b>			
The University of Adelaide	A Precision Medicine Based Approach to Treat Craniosynostosis in Children	\$ 441,370.75	3 (Stream 3)
University of South Australia	Assessment of new treatment options for the childhood cancer Neuroblastoma	\$ 982,101.20	3 (Stream 3)
South Australian Health and Medical Research Institute Limited	Engineered human stem cells for mutation-specific eradication of myelofibrosis	\$ 853,274.50	3 (Stream 3)
Murdoch Children's Research Institute	Insights into CDKL5 neuronal regulation: pathways to improving neurological outcomes for CDKL5 Deficiency Disorder	\$ 854,205.00	3 (Stream 3)
University of Melbourne	iPSC clinical trials - population wide screening of patient iPSC's to reassess high value drug targets for motor neuron disease	\$ 1,000,000.00	3 (Stream 3)
Murdoch Children's Research Institute	New therapies preventing heart damage during chemotherapy	\$ 879,205.45	3 (Stream 3)
University of Wollongong	Novel SMART AAV vectors for gene therapy for Friedreich's Ataxia	\$ 982,861.60	3 (Stream 3)
University of Sydney	Stem Cell Derived-Retinal Organoids to Test Novel Genetic Therapies	\$ 498,419.00	3 (Stream 3)
Murdoch Children's Research Institute	Stem cell models of glomerular kidney disease for understanding disease and developing treatments	\$ 934,253.30	3 (Stream 3)

Institution	Project Title	Amount (ex GST)	Funded from Grant Opportunity
University of Queensland	Transforming the paradigm of epilepsy care with precision medicine	\$ 999,807.95	3 (Stream 3)
The University of Adelaide	Bioengineering a Superior Humanized Haematopoietic Niche Derived from Mesenchymal Stem Cells for Pre-Clinical Avatar Cancer Trials	\$ 854,593.92	5 (Stream 2)
University of New South Wales	Bioengineered tissue models to identify new antiarrhythmics for atrial fibrillation	\$ 979,564.92	5 (Stream 2)
The University of Queensland	Moon's Mission: creating a replicable therapeutic framework for hereditary spastic paraplegias	\$ 940,424.52	5 (Stream 2)
Murdoch Children's Research Institute	Novel human stem cell-based models of genetic cardiomyopathy as a platform for disease modelling and therapeutic development	\$ 732,251.00	5 (Stream 2)
Flinders University	Pre-clinical iPSC-neuron screen of repurposed drugs for children with a form of dementia	\$ 738,228.02	5 (Stream 2)
St Vincent's Institute of Medical Research	Repurposing Clinical Grade Medications for Treatment of Friedreich Ataxia Heart Disease	\$ 812,364.52	5 (Stream 2)
<b>Implementation Plan Priority Area 2.2</b>			
Monash University	Discovering new drugs for epilepsy using personalised medicine	\$ 556,460.60	1 (Stream 2)
University of Melbourne	Identifying novel therapeutic targets in leukaemia stem cells	\$ 894,180.00	1 (Stream 2)
University of Melbourne	Translating patient stem cells into personalised screens for age-related macular degeneration	\$ 881,906.60	1 (Stream 2)

Institution	Project Title	Amount (ex GST)	Funded from Grant Opportunity
QIMR Berghofer	Preventing Cardiac Injury in Patients with COVID-19	\$ 389,998.50	2
University of Melbourne	Stem cell-derived human tissue models for the identification of drugs to treat COVID-19	\$ 610,000.00	2
Commonwealth Scientific and Industrial Research Organisation	The sySTEMs initiative: systems biology-augmented, stem cell-derived, multi-tissue panel for rapid screening of approved drugs as potential COVID-19 treatments	\$ 998,355.93	3 (Stream 5)
Griffith University	Drug discovery for schizophrenia using patient-derived stem cells	\$ 1,425,156.50	4 (Stream 2)
University of Western Australia	Eyes and Ears: a human retinal and inner ear organoid platform for pre-clinical screening of novel therapeutics for Usher Syndrome	\$ 2,215,017.62	4 (Stream 2)
Monash University	Pre-clinical evaluation of selective adenosine A1 receptor positive allosteric modulators for the treatment of drug-resistant epilepsy	\$ 3,849,003.60	4 (Stream 2)
<b>Implementation Plan Priority Area 3.1</b>			
The University of Adelaide	Based Model for Building Trust in Australian Stem Cell Research and Therapies	\$ 995,406.75	3 (Stream 4)
University of Sydney	Improving decisions about access to stem cell interventions	\$ 799,543.40	3 (Stream 4)